CLISSA, CRISTINA
 Distribuzione geografica
Continente #
EU - Europa 1.593
NA - Nord America 1.550
AS - Asia 699
AF - Africa 119
SA - Sud America 4
OC - Oceania 1
Totale 3.966
Nazione #
US - Stati Uniti d'America 1.541
GB - Regno Unito 440
IT - Italia 322
SE - Svezia 296
CN - Cina 265
VN - Vietnam 195
DE - Germania 184
SG - Singapore 100
IN - India 73
IE - Irlanda 57
RU - Federazione Russa 53
TG - Togo 46
FR - Francia 45
GR - Grecia 40
ZA - Sudafrica 34
NG - Nigeria 27
UA - Ucraina 27
EE - Estonia 24
JO - Giordania 22
CH - Svizzera 19
BG - Bulgaria 17
FI - Finlandia 16
AT - Austria 14
BE - Belgio 14
HR - Croazia 14
CA - Canada 9
IR - Iran 9
KR - Corea 9
NL - Olanda 7
PH - Filippine 6
SC - Seychelles 6
CI - Costa d'Avorio 5
TR - Turchia 4
BR - Brasile 3
IL - Israele 3
JP - Giappone 3
LB - Libano 3
HK - Hong Kong 2
AZ - Azerbaigian 1
BD - Bangladesh 1
EC - Ecuador 1
EG - Egitto 1
ID - Indonesia 1
KG - Kirghizistan 1
LU - Lussemburgo 1
MK - Macedonia 1
NZ - Nuova Zelanda 1
PL - Polonia 1
PT - Portogallo 1
UZ - Uzbekistan 1
Totale 3.966
Città #
Southend 418
Chandler 199
Fairfield 180
Ashburn 128
Bologna 114
Woodbridge 92
Houston 91
Wilmington 89
Dong Ket 82
Seattle 80
Ann Arbor 78
Singapore 76
Princeton 74
Cambridge 67
Dublin 57
Lomé 46
Beijing 41
Westminster 40
Padova 37
Nanjing 36
Milan 31
Abeokuta 27
Saint Petersburg 27
Medford 24
Amman 22
New York 20
Berlin 18
Jinan 18
Santa Clara 17
Sofia 17
Helsinki 16
Shenyang 16
Bern 15
Changsha 15
Turin 15
Brussels 14
Jiaxing 14
Redwood City 14
Hebei 12
Vienna 12
Boardman 11
Nanchang 11
Bremen 10
Tappahannock 10
Florence 9
Dearborn 8
Grafing 8
Norwalk 8
San Diego 8
Valsamoggia 8
Frankfurt am Main 7
Haikou 7
Tianjin 7
Athens 6
Davao City 6
Falls Church 6
Hangzhou 6
Jacksonville 6
Mahé 6
North York 6
Zhengzhou 6
Abidjan 5
Bühl 5
Hefei 5
Amsterdam 4
Andover 4
Fuzhou 4
Istanbul 4
Mülheim 4
Riolo Terme 4
Shanghai 4
Taizhou 4
Busto Arsizio 3
Faenza 3
Kunming 3
Los Angeles 3
Merano 3
Taglio Di Po 3
Taiyuan 3
Wuhan 3
Zanjan 3
Brescia 2
Calderara Di Reno 2
Cesena 2
Dehradun 2
Dongguan 2
Guangzhou 2
Gussago 2
Holon 2
Hong Kong 2
Imola 2
Langfang 2
Las Vegas 2
Lausanne 2
Leawood 2
Moscow 2
Mountain View 2
Ningbo 2
Parma 2
Portici 2
Totale 2.661
Nome #
Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience 214
Clinical Impact of Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes 212
Activation of nuclear inositide signalling pathways during erythropoietin therapy in low-risk MDS patients 189
Efficacy and clinical outcome of Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with second generation tyrosine kinase inhibitors (TKIs): The Bologna experience 151
Strategic Role of Nuclear Inositide Signalling in Myelodysplastic Syndromes Therapy 141
Molecular Characterization of High-Risk MDS Patients Treated with Azacitidine and Lenalidomide: Role of Inositide-Dependent Signalling, Mutations and Microrna 135
Computed tomographic pulmonary angiography for diagnosis of invasive mold diseases in patients with hematological malignancies 130
CLINICAL OUTCOME OF T-ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA (T-ALL/TLBL): THE BOLOGNA EXPERIENCE 128
An increased expression of PI-PLCβ1 is associated with myeloid differentiation and a longer response to azacitidine in myelodysplastic syndromes 127
Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen 124
Azacitidine Low-Dose Schedule In Low-Risk Myelodysplastic Syndromes. Preliminary Results of a Multicenter Phase II Study 124
Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen 122
Azacitidine in Myelodysplastic Syndromes: Multicenter Retrospective Study of 34 Long-Responder Patients 119
Early Increase of Phospholipase Cbeta1 (PI-PLCbeta1) Gene Expression Predicts Azacitidine Responsiveness in MDS Patients 113
Nuclear inositide signaling in myelodysplastic syndromes. 111
Effect of Lenalidomide Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients 109
EFFICACY, FEASIBILITY AND SAFETY OF NELARABINE SAVAGE THERAPY IN ADULT RELAPSED OR REFRACTORY T CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL) OR LYMPHOBLASTIC LYMPHOMA (T-LBL): THE BOLOGNA EXPERIENCE 106
DIFFERENTIAL EFFECT OF LENALIDOMIDE ON INDUCTION OF INOSITIDE-DEPENDENT ERYTHROPOIESIS AND CELL CYCLE IN MYELODYSPLASTIC SYNDROMES 106
Epigenetic regulation of nuclear inositide signalling in high-risk MDS patients 104
null 103
Inositide-dependent signaling pathways as new therapeutic targets in myelodysplastic syndromes 103
Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harbouring T315I Mutation: The Bologna Experience 101
Nelarabine is safe and effective in adult relapsed or refractory T cellacute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (T-LBL): The Bologna experience 101
Epigenetic Regulation of Lipid Signalling Pathways In Low-Risk MDS Patients During Azacitidine Treatment 99
Phosphoinositide-phospholipase C beta1 mono-allelic deletion is associated with myelodysplastic syndromes evolution into acute myeloid leukemia. 97
Effect of Erythropoietin Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients. 96
null 93
Nelarabine Is Safe and Effective In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL): The Bologna Experience 83
Nuclear PI-PLC β1 and Myelodysplastic Syndromes: From Bench to Clinics 73
NELARABINE IS SAFE AND EFFECTIVE IN ADULT RELAPSED OR REFRACTORY T CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL) AND LYMPHOBLASTIC LYMPHOMA (T-LBL): THE BOLOGNA EXPERIENCE 73
null 71
CLONAL ACTIVATION OF AKT IN LOW-RISK MDS PATIENTS WITH DEL(5Q) TREATED WITH LENALIDOMIDE 68
PI-PLCbeta1 Expression in Patients with High-Risk Myelodysplastic Syndromes Is Affected by Azacitidine Treatment. 68
[Molecular biology in myelodysplastic syndromes and acute myeloid leukemias "smoldering"] 67
RASGRP1/APTX ratio is a strong biomarker which predicts response to therapy with Tipifarnib plus Bortezomib in elderly patients with Acute Myeloid Leukemia (AML) 67
NELARABINE FRONT-LINE THERAPY FOR ADULT T-LYMPHOBLASTIC LEUKAEMIA/LYMPHOMA (T-LBL/ALL): PRELIMINARY RESULTS OF BOLOGNA EXPERIENCE 65
EFFICACY AND CLINICAL OUTCOME OF PHILADELPHIA (PH) POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS TREATED WITH SECOND GENERATION TYROSINE KINASE INHIBITORS (TKIS): THE BOLOGNA EXPERIENCE 42
Nuclear translocation of PKC-alpha is associated with cell cycle arrest and erythroid differentiation in myelodysplastic syndromes (MDSs) 28
Totale 4.063
Categoria #
all - tutte 9.760
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.760


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020798 0 0 0 77 92 117 102 85 132 67 66 60
2020/2021520 100 24 5 7 23 14 16 35 50 25 9 212
2021/2022778 84 11 52 86 78 48 19 38 39 72 120 131
2022/2023898 73 132 44 115 74 67 34 92 146 9 74 38
2023/2024310 7 45 22 32 41 62 10 19 20 18 19 15
2024/2025205 38 74 74 19 0 0 0 0 0 0 0 0
Totale 4.063